The hybrid retreat showcased the latest gastric cancer, blood cancer, pediatric sarcoma, glioblastoma, breast cancer, and immune micro-environment research.
Duke Neurosurgery researchers have identified a driver of resistance to immunotherapies in deadly brain tumors, which could be targeted — allowing this type of drug to do its work.
While considered a single ethnic group, the differences found in the occurrence and outcomes of glioma brain tumor patients suggests important diversity.
The V Foundation's Victory Ride to Cure Cancer was back as a LIVE cycling event and celebration, Aug. 28. Team DCI "virtual" and in-person riders raised more than $20K.
This OHE-hosted talk featured director of the Patierno/George/Freedman Lab Jennifer Freedman, PhD, and postdocs Tyler Allen, PhD, and Sean Piwarski, PhD.
The authors, including corresponding author Madan Kwatra, MD, report that osimertinib inhibits the constitutive activity of EGFRv III tyrosine kinase with high potency.
David M. Ashley, PhD, was recently named director of The Preston Robert Tisch Brain Tumor Center. He succeeds Darell Bigner, MD, PhD, who became direc...
In July NCATS announced nearly $3 million to fund cooperative agreements with four academic research groups to conduct pre-clinical validation studies...
Glioblastoma brain tumors can have an unusual effect on the body’s immune system, often causing a dramatic drop in the number of circulating T-cells t...
Biomedical engineers at Duke University have recruited an unlikely ally in the fight against the deadliest form of brain cancer — a strain of salmonel...
Jacksonville, Florida, resident Oren Margol loved nothing more than getting out with his buddies for a game of golf. In fact, he and his friends event...
If 43-year-old Gabe Stewart were a matador, he would likely be a bull’s worst enemy. Just ask his wife of 19 years, Tera, or his two kids, a 13-year-o...
Most glioblastoma tumors are marked by one or two broad mutation patterns, but about 20 percent of the lethal brain tumors have biomarkers that cannot...
The recombinant poliovirus therapy developed at the Preston Robert Tisch Brain Tumor Center at Duke Health has been granted “breakthrough therapy desi...
A phase one study of 11 patients with glioblastoma who received injections of an investigational vaccine therapy and an approved chemotherapy showed t...
A genetically modified poliovirus therapy developed at Duke Cancer Institute shows significantly improved long-term survival for patients with recurre...